Physician profile
Robert L Cater
NPI 1053474452
$1,511.82
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $164 · 2021: $215 · 2022: $267 · 2023: $397 · 2024: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $344.02 | 2020-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $280.62 | 2019-2024 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $234.34 | 2020-2024 | Mounjaro |
| Mayne Pharma Commercial LLC | $84.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.58 | 2022-2023 | |
| Amgen INC. | $81.60 | 2020 | |
| Stryker Corporation | $72.83 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.25 | 2019-2020 | |
| Glaxosmithkline, LLC. | $52.93 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Melinta Therapeutics, LLC | $31.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.19 | 2022-2023 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $29.77 | 2022 | |
| Boston Scientific Corporation | $26.18 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.27 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $18.20 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.62 | 2021 | |
| Pfizer INC. | $15.49 | 2023 | |
| Genentech USA, INC. | $12.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.18 | 2019 | |
| Merck Sharp & Dohme LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.